首页> 外文期刊>The American journal of Chinese medicine >An aqueous extract of Portulaca oleracea ameliorates diabetic nephropathy through suppression of renal fibrosis and inflammation in diabetic db/db mice
【24h】

An aqueous extract of Portulaca oleracea ameliorates diabetic nephropathy through suppression of renal fibrosis and inflammation in diabetic db/db mice

机译:马齿ula的水提物可通过抑制糖尿病db / db小鼠的肾纤维化和炎症改善糖尿病性肾病

获取原文
获取原文并翻译 | 示例

摘要

Diabetic nephropathy is one of the most common microvascular complications of diabetes and the leading cause of end-stage renal disease. In the present study, we investigated the renoprotective effect of the aqueous extract of Portulaca oleracea (AP) on diabetic nephropathy accelerated by renal fibrosis and inflammation in type 2 diabetic db/db mice. The mice were treated with AP (300 mg/kg/day, p.o.) for ten weeks to examine the long-term effects on diabetic nephropathy and renal dysfunction. We found that AP treatment markedly lowered blood glucose to 412 ± 11.4 mg/dl and plasma creatinine level to 2.3 ± 0.8 mg/dl compared to db/db mice (p < 0.05, p < 0.01, respectively). This study also showed that treatment with AP significantly decreased water intake and urine volume in diabetic db/db mice (p < 0.05). In immunohistological study, the renal expression of transforming growth factor-β1 (TGF-β1), advanced glycation end products (AGE), and intercellular adhesion molecule (ICAM)-1 markedly increased in the renal cortex of untreated db/db mice (p < 0.01). In contrast, AP treatment significantly reduced these expressions to 50 ± 2.1%, 48 ± 2.8%, 61 ± 1.1%, respectively (p < 0.01). Furthermore, NF-κB p65 activation in renal tissues markedly increased in untreated db/db mice, which was significantly suppressed by AP treatment. Taken together, these findings suggest that AP attenuates diabetic nephropathy through inhibition of renal fibrosis and inflammation in db/db mice.
机译:糖尿病肾病是糖尿病最常见的微血管并发症之一,也是终末期肾脏疾病的主要原因。在本研究中,我们调查了马齿Port水提物(AP)对2型糖尿病db / db小鼠肾纤维化和炎症促进的糖尿病肾病的肾脏保护作用。用AP(300 mg / kg / day,p.o.)治疗小鼠十周,以检查对糖尿病性肾病和肾功能不全的长期影响。我们发现,与db / db小鼠相比,AP治疗显着降低了血糖至412±11.4 mg / dl和血浆肌酐水平至2.3±0.8 mg / dl(分别为p <0.05,p <0.01)。这项研究还表明,用AP治疗可显着降低糖尿病db / db小鼠的饮水量和尿量(p <0.05)。在免疫组织学研究中,未经处理的db / db小鼠的肾皮质中转化生长因子-β1(TGF-β1),晚期糖基化终产物(AGE)和细胞间粘附分子(ICAM)-1的肾脏表达显着增加(p <0.01)。相反,AP治疗将这些表达分别显着降低至50±2.1%,48±2.8%,61±1.1%(p <0.01)。此外,在未经治疗的db / db小鼠中,肾组织中的NF-κBp65激活显着增加,而AP治疗可显着抑制NF-κBp65的激活。综上所述,这些发现表明AP通过抑制db / db小鼠的肾纤维化和炎症来减轻糖尿病性肾病。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号